NVGN Profile
Novogen
Limited, trading under the ticker symbol NVGN, was a biotechnology
company that focused on the development of drugs for the treatment of
cancer and other diseases. The company was headquartered in Sydney,
Australia, and had a subsidiary in the United States.
Novogen's
lead drug candidate was Cantrixil, a drug that was being developed for
the treatment of ovarian cancer. The company also had other drug
candidates in its pipeline that were being developed for the treatment
of various cancers.
In 2017, Novogen merged with its
subsidiary, to form Kazia Therapeutics Limited, and the company was
delisted from the NASDAQ stock exchange.
Prior to its merger,
as of its most recent financial filings, Novogen had a market
capitalization of approximately $12 million and employed over 40
professionals across its various operations worldwide. The company
faced challenges in securing funding for its research and development
activities and in successfully developing and commercializing its drug
candidates.
Investors who held NVGN stock should have received
compensation from the merger. Investors who are interested in the
biotechnology industry may want to research other publicly traded
companies in the sector, evaluate their financial performance,
competitive position, and growth prospects. The biotechnology industry
is highly competitive, and the success of a company's research and
development activities is
|
